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CXA-101, a novel oxyimino-aminothiazolyl cephalosporin, CXA-201 (CXA-101 combined with tazobactam),
and various comparators were susceptibility tested by broth microdilution methods against 1,301 well-char-
acterized clinical strains collected worldwide, including ceftazidime-resistant members of the family Entero-
bacteriaceae and Klebsiella pneumoniae carbapenemase (KPC)- and extended-spectrum -lactamase (ESBL)-
producing strains of Pseudomonas aeruginosa and Bacteroides fragilis. CXA-201 was 2- to 32-fold more active
than ceftazidime and piperacillin-tazobactam against ceftazidime-resistant Enterobacteriaceae species but less
active than cefepime for some species. CXA-101 and CXA-201 were very active against P. aeruginosa (MIC50,
1 g/ml for both compounds), including imipenem-resistant strains.
CXA-101 (formerly FR264205), a novel oxyimino-aminothia-
zolyl cephalosporin, has shown greater activity (compared to
ceftazidime) against Pseudomonas aeruginosa (1, 6, 7, 10, 11).
CXA-101 has also demonstrated good activity against mem-
bers of the family Enterobacteriaceae, but similar to other oxy-
imino-aminothiazolyl cephalosporins, CXA-101 activity can be
adversely affected by bacterial production of extended-spec-
trum -lactamases (ESBLs) and stably derepressed AmpC
-lactamases (8, 9). Thus, to improve its spectrum against
Enterobacteriaceae and some anaerobic species, such as Bacte-
roides spp., CXA-101 is under clinical development in combi-
nation with tazobactam (CXA-201). In the present study, we
evaluate the potency and spectrum of activity of CXA-101, with
and without tazobactam, and comparator drugs tested against a
contemporary collection of clinically derived Enterobacteriaceae
and P. aeruginosa possessing selected patterns of antimicrobial
resistance, as well as Bacteriodes fragilis wild-type (WT) strains.
The organisms were collected from patients in the United
States, Europe, Latin America, and Asia (2006 to 2008) and
selected based on previously defined antimicrobial susceptibil-
ity patterns. The isolates were recovered from skin and soft
tissue samples and respiratory tract and bloodstream infec-
tions. Enterobacteriaceae isolates were chosen based on resis-
tance to ceftazidime (strains with a MIC of32 g/ml), except
for Proteus mirabilis where isolates demonstrated an ESBL
phenotype, defined as a MIC of 2 g/ml for ceftazidime or
ceftriaxone or aztreonam (5). Furthermore, a collection of 53
Klebsiella pneumoniae strains producing K. pneumoniae car-
bapenemase (KPC) was also included. KPC production was
characterized by the modified Hodge test, PCR, and gene
sequencing as previously described (2). To better evaluate the
activities of CXA-201 (CXA-101 combined with tazobactam) and
CXA-101 against -lactam-resistant P. aeruginosa, strains were
stratified by susceptibility pattern to ceftazidime and imipenem.
MIC values for the aerobic bacilli were determined using the
reference Clinical and Laboratory Standards Institute (CLSI)
broth microdilution method (M07-A8) (4). Quality control
(QC) ranges and interpretive criteria for comparator com-
pounds used the CLSI M100-S21 guidelines (5). For B. fragilis,
MIC values were determined using the reference CLSI broth
microdilution method (M11-A7) (3). CXA-101 (Calixa Ther-
apeutics, San Diego, CA) was tested alone (range, 0.25 to 32
g/ml) and in combination with tazobactam at a fixed concen-
tration of 2 or 4 g/ml and at CXA-101/tazobactam ratios of
2:1, 4:1, and 8:1 against Enterobacteriaceae, while P. aeruginosa
strains were tested against CXA-101 alone (range, 0.12 to 128
g/ml) and combined with tazobactam at a fixed concentration
of 4 g/ml (range, 0.12 to 128 g/ml).
The vast majority of Enterobacteriaceae were resistant to
ceftazidime (94.3%) and ceftriaxone (95.3%) as defined by the
current CLSI breakpoints (5), and the greatest enhanced
effect of tazobactam with CXA-101 was obtained with tazo-
bactam at a fixed concentration of 4 g/ml (CXA-201;
MIC50 of 4/4 g/ml; Table 1). CXA-201 was 2-fold more
potent than cefepime (MIC50 of 8 g/ml; 55.6% susceptible) and
8-fold more active than piperacillin-tazobactam (MIC50 of 32
g/ml; 48.2% susceptible) against this highly resistant collection
of Enterobacteriaceae. The carbapenems (imipenem and mero-
penem) were the most active -lactams tested against these En-
terobacteriaceae; however, only 80.4 and 91.6% of strains were
susceptible to imipenem and meropenem, respectively (Table 1).
CXA-201 showed good in vitro activity against ceftazidime-
resistant Escherichia coli (MIC50, 1 g/ml) and K. pneumoniae
(MIC50, 4 g/ml). Ceftriaxone (0.0 to 1.6% susceptible),
cefepime (33.5 to 53.2% susceptible), and piperacillin-tazobac-
tam (MIC50, 16 to 32 g/ml; 45.2 to 59.4% susceptible) exhib-
ited limited activity, while imipenem and meropenem retained
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good activity against these organisms (97.3% susceptible).
The KPC-producing K. pneumoniae strains were highly resis-
tant to all -lactam agents tested (Table 2).
When tested against ceftazidime-resistant strains of Entero-
bacter and Citrobacter spp., CXA-201 (MIC50, 16 g/ml for
both organism groups) exhibited greater activity than pipera-
cillin-tazobactam (MIC50, 64 g/ml for both organism groups),
ceftriaxone (MIC50, 32 to 32 g/ml), and ceftazidime
(MIC50, 64 g/ml for both organism groups), but it was less
active than cefepime (MIC50, 1 to 2 g/ml), imipenem (MIC50,
0.5 g/ml for both organism groups), and meropenem
(MIC50, 0.12 g/ml for both organism groups) (Table 2).
These strains produced presumptive AmpC enzymes.
CXA-201 activity against P. mirabilis strains with ESBL phe-
notype (MIC50 of 1g/ml and MIC90 of 8g/ml) was comparable
to that of piperacillin-tazobactam (MIC50 of 1 g/ml and MIC90
TABLE 1. MIC distribution for CXA-101 alone and in combination with tazobactam and various comparator agents tested against selected
Enterobacteriaceae species, K. pneumoniae strains, and P. mirabilis strainsa
Antimicrobial
agent(s)b
No. of isolates (cumulative %) inhibited at the following concn (g/ml) of CXA-101 or comparator agentc:
0.12 0.25 0.5 1 2 4 8 16 32 or 16 64 or 32 64
CXA-101 2 (0.3) 6 (1.0) 5 (1.6) 11 (3.0) 35 (7.3) 78 (16.9) 109 (30.33) 136 (47.10) 429 (100.0) —
CXA-101
combinations
CXA-TAZ4 4 (0.5) 36 (4.9) 102 (17.5) 143 (35.1) 83 (45.4) 95 (57.1) 63 (64.9) 95 (76.6) 190 (100.0) — —
CXA-TAZ2 0 (0.0) 24 (3.0) 60 (10.4) 107 (23.6) 76 (32.9) 71 (41.7) 65 (49.7) 128 (65.5) 280 (100.0) — —
CXA-TAZ(2:1) 0 (0.0) 2 (0.3) 13 (1.9) 21 (4.4) 91 (15.7) 209 (41.4) 190 (64.9) 163 (85.0) 122 (100.0) — —
CXA-TAZ(4:1) 0 (0.0) 2 (0.3) 8 (1.2) 19 (3.6) 43 (8.9) 118 (23.4) 225 (51.2) 209 (76.9) 187 (100.0) — —
CXA-TAZ(8:1) 0 (0.0) 1 (0.1) 8 (1.1) 13 (2.7) 24 (5.7) 68 (14.1) 159 (33.7) 247 (64.1) 291 (100.0) — —
Comparator agents
Ceftazidime — — — — — 39 (4.8) 7 (5.7) 4 (6.2) 66 (14.3) 204 (39.5) 491 (100.0)
Ceftriaxone — 11 (1.4) 4 (1.9) 6 (2.6) 17 (4.7) 33 (8.8) 53 (15.3) 102 (27.9) 128 (43.7) 457 (100.0) —
Cefepime 44 (5.4) 40 (10.4) 81 (20.6) 98 (32.4) 91 (43.7) 51 (49.9) 46 (55.6) 58 (62.8) 302 (100.0) — —
Imipenem — — 548 (67.6) 104 (80.4) 74 (89.5) 24 (92.5) 13 (94.1) 48 (100.0) — — —
Meropenem 685 (79.4) 38 (89.3) 14 (91.0) 5 (91.6) 7 (92.5) 7 (93.3) 10 (94.6) 44 (100.0) — — —
Piperacillin-
tazobactam
— — — 78 (9.6) 51 (15.9) 78 (25.5) 74 (34.7) 110 (48.2) 93 (59.7) 95 (71.4) 232 (100.0)
a CXA-101 alone and in combination with tazobactam and various comparator agents were tested against 690 ceftazidime-resistant strains from selected Entero-
bacteriaceae species, 53 KPC-producing K. pneumoniae strains, and 68 ESBL-producing P. mirabilis strains. The selected Enterobacteriaceae species include E. coli (224
strains), K. pneumoniae (186 strains), indole-positive Proteus (82 strains), Enterobacter spp. (90 strains), and Citrobacter spp. (108 strains).
b CXA-101 alone and in combination with tazobactam (TAZ) were tested as follows: CXA-TAZ4 and CXA-TAZ2, CXA-101 and tazobactam with taxobactam at
a fixed concentration of 4 g/ml and 2 g/ml, respectively; CXA-TAZ(2:1), CXA-TAZ(4:1), and CXA-TAZ(8:1), CXA-101 and tazobactam at ratios of 2:1, 4:1, and
8:1, respectively.
c The MIC50s are underlined. —, concentration not tested.
TABLE 2. MIC distributions of CXA-201 tested against ceftazidime-resistant Enterobacteriaceae, ESBL-producing
P. mirabilis, P. aeruginosa, and B. fragilisa
Organism (no. tested)b
No. of isolates (cumulative %) inhibited at the following CXA-101–tazobactam MIC (g/ml)c:
0.12 0.25 0.5 1 2 4 8 16 16
E. coli, CAZ-R (224) 2 (0.9) 5 (3.1) 42 (21.9) 72 (54.0)b 35 (69.6) 18 (77.7) 18 (85.7) 14 (92.0) 18 (100.0)
K. pneumoniae strains
CAZ-R (186) 2 (1.1) 6 (4.3) 20 (15.1) 33 (32.8) 18 (42.5) 22 (54.3) 10 (59.7) 16 (68.3) 59 (100.0)
KPC producers (53) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (3.8) 51 (100.0)
Proteus, indole positive,
CAZ-R (82)
0 (0.0) 12 (14.6) 8 (24.4) 10 (36.6) 15 (54.9) 12 (69.5) 7 (78.0) 5 (84.1) 13 (100.0)
Enterobacter spp., CAZ-R (90) 0 (0.0) 6 (6.7) 2 (8.9) 6 (15.6) 3 (18.9) 16 (36.7) 11 (48.9) 25 (76.7) 21 (100.0)
Citrobacter spp., CAZ-R (108) 0 (0.0) 2 (1.9) 2 (3.7) 7 (10.2) 5 (14.8) 22 (35.2) 13 (47.2) 31 (75.9) 26 (100.0)
P. mirabilis with the ESBL
phenotype (68)
0 (0.0) 5 (7.3) 28 (48.5) 15 (70.6) 7 (80.9) 5 (88.2) 4 (94.1) 2 (97.1) 2 (100.0)
P. aeruginosa (449) 0 (0.0) 7 (1.6) 131 (30.7) 113 (55.9) 84 (74.6) 57 (87.3) 25 (92.9) 8 (94.7) 24 (100.0)
CAZ-S, IMI-S (54) 0 (0.0) 6 (11.1) 45 (94.4) 2 (98.2) 1 (100.0)
CAZ-S, IMI-NS (143) 0 (0.0) 3 (2.1) 75 (54.6) 58 (95.1) 3 (97.2) 0 (0.0) 3 (99.3) 1 (100.0)
CAZ-NS, IMI-S (39) 0 (0.0) 0 (0.0) 1 (2.6) 10 (28.2) 13 (61.5) 7 (79.5) 2 (84.6) 1 (87.2) 5 (100.0)
CAZ-NS, IMI-NS (213) 0 (0.0) 0 (0.0) 5 (2.4) 38 (20.2) 60 (48.4) 58 (75.6) 24 (86.9) 7 (90.9) 21 (100.0)
B. fragilis (41) 1 (7.4) 4 (12.2) 5 (24.4) 15 (61.0) 4 (70.7) 0 (70.7) 2 (75.6) 2 (80.5) 8 (100.0)
a In this experiment, the concentration of tazobactam was fixed at 4 g/ml.
b Abbreviations: CAZ-R, ceftazidime-resistant; KPC, Klebsiella pneumoniae carbapenemase; ESBL, extended-spectrum -lactamase (5); CAZ-S, ceftazidime-
susceptible; CAZ-NS, ceftazidime-nonsusceptible; IMI-S, imipenem-susceptible; IMI-NS, imipenem-nonsusceptible.
c The MIC50s are underlined.
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TABLE 3. Antimicrobial activity of CXA-101 alone or combined with tazobactam at a fixed concentration of 4 g/ml and
various comparator agents
Organism (no. tested) and antimicrobial agent(s) MIC50 (g/ml) MIC90 (g/ml) MIC range (g/ml) % susceptiblea % resistanta
E. coli, ceftazidime-resistant strains (224)
CXA-TAZ4b 1 16 0.12–16 — —
CXA-101 32 32 1–32 — —
Ceftazidime 64 64 32–64 0.0 100.0
Ceftriaxone 32 32 1–32 0.0 99.5
Cefepime 16 16 0.25–16 33.5 59.4
Imipenem 0.5 0.5 0.5–8 98.2 0.5
Meropenem 0.12 0.12 0.015–8 98.7 0.9
Piperacillin-tazobactam 16 64 1–64 59.4 17.4
K. pneumoniae, ceftazidime-resistant strains (186)
CXA-TAZ4 4 16 0.12–16 — —
CXA-101 32 32 4–32 — —
Ceftazidime 64 64 32–64 0.0 100.0
Ceftriaxone 32 32 0.5–32 1.6 97.3
Cefepime 8 16 0.25–16 53.2 39.2
Imipenem 0.5 0.5 0.5–8 97.9 2.1
Meropenem 012 0.12 0.12–8 97.3 1.6
Piperacillin-tazobactam 32 64 1–64 45.2 33.9
K. pneumoniae, KPC-producing strains (53)
CXA-TAZ4 16 16 16–16 — —
CXA-101 32 32 32–32 — —
Ceftazidime 64 64 64–64 0.0 100.0
Ceftriaxone 32 32 16–32 0.0 100.0
Cefepime 16 16 4–16 11.3 71.7
Imipenem 8 8 4–8 0.0 100.0
Meropenem 8 8 2–8 0.0 98.1
Piperacillin-tazobactam 64 64 64 0.0 100.0
Proteus, indole-positive, ceftazidime-resistant strains (82)
CXA-TAZ4 2 16 0.25–16 — —
CXA-101 32 32 4–32 — —
Ceftazidime 64 64 32–64 0.0 100.0
Ceftriaxone 8 32 0.25–32 2.4 87.8
Cefepime 0.5 16 0.12–16 86.6 8.5
Imipenem 2 4 0.5–8 34.2 14.6
Meropenem 0.12 0.25 0.12–2 97.6 0.0
Piperacillin-tazobactam 4 64 0.25–64 70.7 8.5
Enterobacter spp., ceftazidime-resistant strains (90)
CXA-TAZ4 16 16 0.25–16 — —
CXA-101 32 32 4–32 — —
Ceftazidime 64 64 32–64 0.0 100.0
Ceftriaxone 32 32 8–32 0.0 100.0
Cefepime 2 16 0.25–16 71.1 20.0
Imipenem 0.5 1 0.5–8 95.6 3.3
Meropenem 0.12 0.25 0.12–4 96.7 2.2
Piperacillin-tazobactam 64 64 2–64 16.7 38.9
Citrobacter spp., ceftazidime-resistant strains (108)
CXA-TAZ4 16 16 0.25–16 — —
CXA-101 32 32 1–32 — —
Ceftazidime 64 64 32–64 0.0 100.0
Ceftriaxone 32 32 4–32 3.7 44.4
Cefepime 1 16 0.12–16 88.9 7.4
Imipenem 0.5 1 0.5–8 99.1 0.0
Meropenem 0.12 0.12 0.12–4 100.0 0.0
Piperacillin-tazobactam 64 64 1–64 32.4 32.4
P. mirabilis strains with ESBL phenotype (68)
CXA-TAZ4 1 8 0.25–16 — —
CXA-101 8 32 0.25–32 — —
Ceftazidime 4 64 4–64 57.4 32.4
Ceftriaxone 8 32 0.25–32 23.5 64.7
Continued on following page
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of 8 g/ml; 97.1% susceptible; Table 2). Ceftazidime (MIC50, 32
g/ml) and CXA-101 (MIC50, 32 g/ml) exhibited limited ac-
tivity against B. fragilis. In contrast, CXA-201 inhibited 70.7% of
strains at 2 and 4 g/ml or less for its components, CXA-101 and
taxobactam, respectively (Tables 1 and 2).
CXA-101 demonstrated potent in vitro activity against
P. aeruginosa strains, and the addition of tazobactam did not
produce significant enhancement of activity (Table 3). CXA-
101 and CXA-201 (MIC50 of 1 g/ml and MIC90 of 8 g/ml)
were at least 8-fold more active than ceftazidime (MIC50 of 8
TABLE 3—Continued
Organism (no. tested) and antimicrobial agent(s) MIC50 (g/ml) MIC90 (g/ml) MIC range (g/ml) % susceptiblea % resistanta
Cefepime 4 16 0.12–16 58.8 36.8
Imipenem 2 4 0.5–4 45.6 14.7
Meropenem 0.12 0.12 0.12–8 98.5 1.5
Piperacillin-tazobactam 1 8 0.5–32 97.1 0.0
P. aeruginosa
All strains (449)
CXA-TAZ4 1 8 0.25–128 — —
CXA-101 1 8 0.25–128 — —
Ceftazidime 16 128 1–128 43.9 46.3
Cefepime 8 16 0.5–16 51.2 24.7
Imipenem 8 8 0.5–8 20.7 59.7
Doripenem 8 16 0.06–32 21.2 52.8
Piperacillin-tazobactam 32 64 1–64 62.6 37.4
Ceftazidime- and imipenem-susceptible strains (54)
CXA-TAZ4 0.5 0.5 0.25–2 — —
CXA-101 0.5 0.5 0.25–2 — —
Ceftazidime 2 4 1–8 100.0 0.0
Cefepime 2 4 0.5–16 98.2 0.0
Imipenem 1 2 0.5–4 100.0 0.0
Doripenem 0.25 1 0.06–1 100.0 0.0
Piperacillin-tazobactam 4 8 1–32 100.0 0.0
Ceftazidime-susceptible, imipenem-nonsusceptible
strains (143)
CXA-TAZ4 0.5 1 0.25–8 — —
CXA-101 0.5 1 0.25–16 — —
Ceftazidime 8 8 2–8 100.0 0.0
Cefepime 8 16 1–16 87.4 3.5
Imipenem 8 8 8–8 0.0 72.0
Doripenem 4 8 2–16 3.5 35.7
Piperacillin-tazobactam 16 64 2–64 90.9 9.1
Ceftazidime-nonsusceptible, imipenem-susceptible
strains (39)
CXA-TAZ4 2 64 0.5–128 — —
CXA-101 2 128 0.25–128 — —
Ceftazidime 64 128 16–128 7.7 92.3
Cefepime 16 16 4–16 25.6 41.0
Imipenem 1 4 0.5–4 100.0 0.0
Doripenem 1 4 0.25–8 87.2 5.1
Piperacillin-tazobactam 64 64 16–64 59.0 41.0
Ceftazidime- and imipenem-nonsusceptible strains (213)c
CXA-TAZ4 2 16 0.5–128 — —
CXA-101 4 16 0.5–128 — —
Ceftazidime 64 128 16–128 0.0 80.7
Cefepime 16 16 4–16 19.7 42.3
Imipenem 8 8 8–8 0.0 77.5
Doripenem 8 32 2–32 0.9 86.4
Piperacillin-tazobactam 64 64 8–64 34.7 65.3
B. fragilis strains (41)
CXA-TAZ4 1 16 0.12–16 — —
CXA-101 32 32 1–32 — —
Ceftazidime 32 64 8–64 — —
a The percentages of susceptible and resistant organisms according to CLSI breakpoints (5) are shown. —, no published interpretive criteria.
b CXA-TAZ4, CXA-101 combined with tazobactam at fixed concentration of 4 g/ml.
c Imipenem MIC of 8 g/ml and ceftazidime MIC of 16 g/ml. CLSI breakpoints (5) were used.
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g/ml and MIC90 of 128 g/ml) and doripenem (MIC50 of 8
g/ml and MIC90 of 16 g/ml) when tested against the entire
collection of P. aeruginosa strains (Table 3). When tested
against P. aeruginosa strains susceptible to ceftazidime and
imipenem, CXA-201 (MIC50 and MIC90 of 0.5 g/ml) was 4- to
8-fold more active than ceftazidime and cefepime (MIC50 of 2
g/ml and MIC90 of 4 g/ml), 8- to 16-fold more active than
piperacillin-tazobactam (MIC50 of 4 g/ml and MIC90 of 8
g/ml), and 2- to 4-fold more active than imipenem (MIC50 of
1 g/ml and MIC90 of 2 g/ml) while demonstrating activity
comparable to that of doripenem (MIC50 of 0.25 g/ml and
MIC90 of 1 g/ml). P. aeruginosa strains that were not suscep-
tible to imipenem and susceptible to ceftazidime remained
highly susceptible to CXA-201 and CXA-101 (MIC50 of 0.5
g/ml and MIC90 of 1 g/ml) (Table 3).
Against ceftazidime-resistant strains, CXA-201 (MIC50 of 2
g/ml and MIC90 of 16 to 64 g/ml) was 32-fold more active
than ceftazidime (MIC50, 64 g/ml) and retained good activity
against the majority of strains. Interestingly, 75.6 and 85.9% of
P. aeruginosa strains resistant to both ceftazidime and imi-
penem were inhibited at 4 and 8 g/ml of CXA-201, re-
spectively (Table 3). CXA-201 (MIC50 of 2 g/ml and MIC90
of 16 g/ml) and CXA-101 (MIC50 of 4 g/ml and MIC90 of 16
g/ml) were the most active compounds tested against this
highly selected group of resistant P. aeruginosa strains, fol-
lowed in activity by doripenem (MIC50 of 8 g/ml and MIC90
of 32 g/ml) and cefepime (MIC50 of 16 g/ml and MIC90 of
16 g/ml) (Table 3).
CXA-101 has demonstrated potent anti-P. aeruginosa activ-
ity in previous studies (1, 7, 10, 11); however, like long-estab-
lished oxyimino-cephalosporins, it is compromised by ESBLs,
derepressed AmpC enzymes, and carbapenemases, such as
KPCs and metallo--lactamases (8). To decrease this vul-
nerability, CXA-101 was combined with tazobactam, a
-lactamase inhibitor with established safety and efficacy
when associated with piperacillin. As anticipated, the ma-
jority of ceftazidime-resistant Enterobacteriaceae and ESBL-
producing P. mirabilis strains exhibited elevated CXA-101
MIC values (only 16.9% of strains inhibited at 8 g/ml of
CXA-101). However, the addition of tazobactam (CXA-201)
markedly extended the spectrum of CXA-101 against this large
collection of -lactamase-producing strains, and 64.9% of
strains were inhibited at 8/4 g/ml (Table 1). Synergism
effects were more evident among ESBL-producing organisms,
such as E. coli, K. pneumoniae, and P. mirabilis. Some inhibi-
tory activity was also observed with AmpC-derepressed Entero-
bacter and Citrobacter strains; however, CXA-201 MIC values
remained elevated (16 g/ml) for approximately one-half of
the tested organisms.
Our results indicate that CXA-101 alone and CXA-TAZ4
(CXA-101 with taxobactam at a fixed concentration of 4 g/
ml) are more potent than ceftazidime and cefepime against P.
aeruginosa (1, 10). Against strains susceptible to ceftazidime
and imipenem, CXA-101 and CXA-201 were 4- to 8-fold more
active than these commonly used antipseudomonal cephalo-
sporins. Furthermore, the in vitro activities of CXA-101 and
CXA-201 were not adversely affected by resistance to the car-
bapenems. Although CXA-101 and CXA-201 MIC values were
higher for ceftazidime-resistant organisms than for their cef-
tazidime-susceptible counterparts, it appears that these com-
pounds retain activity against some P. aeruginosa strains resis-
tant to ceftazidime. CXA-201 was the most active compound
tested against strains resistant to both ceftazidime and imi-
penem with MIC50s of only 2 and 4 g/ml for its components,
CXA-101 and tazobactam, respectively.
In summary, these data for CXA-201 tested against various
-lactam-resistant strains of Enterobacteriaceae and P. aerugi-
nosa are encouraging; most importantly, CXA-201 demon-
strated enhanced anti-P. aeruginosa activity compared to cef-
tazidime and cefepime. Initial results from pharmacokinetics
and safety studies are also promising (6), indicating the poten-
tial usefulness of CXA-201 for the treatment of some infec-
tions caused by multidrug-resistant (MDR) Gram-negative or-
ganisms.
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